Acasti Pharma (ACST-X) Stock Predictions - Stockchase
WATCH LIST
8
Acasti Pharma (ACST-X)

ON STOCKCHASE SINCE Sep 2013

Consumer Products

Acasti Pharma

ACST-X

7 watching          
Join the Discussion

Acasti Pharma (ACST-X) SAVE Jan, 23, 2019, 3:24 am

1.43 0.04 (2.88%)

What the experts are saying about ACST-X



  • All
  • Filtered
Signal Opinion Expert
BUY
Acasti Pharma(ACST-X) 

September 5, 2018

Pretty disappointing after last fall's announcement to have an Asian pharma company come in and get the rights to CaPre, their phase-3 development drug to treat cholesterol. It looked promising, but ACST hold off on the deal after a few new parties showed interest in CaPre. The market is disappointed the deal didn't happen and punished this stock. He believes this company could be worth $1 billion in two three years. The promise is still there, but you have to wait. Watch the phase 3 drug trials into next year.

Consumer Products
0 0 0 0 0
0 comments

Pretty disappointing after last fall's announcement to have an Asian pharma company come in and get the rights to CaPre, their phase-3 development drug to treat cholesterol. It looked promising, but ACST hold off on the deal after a few new parties showed interest in CaPre. The market is disappointed the deal didn't happen and punished this stock. He believes this company could be worth $1 billion in two three years. The promise is still there, but you have to wait. Watch the phase 3 drug trials into next year.

Consumer Products
0 0 0 0 0
0 comments
Alex Ruus

Portfolio , Arrow Capital Manage...

Price Price
$0.720
Owned Owned
Yes

TOP PICK
Acasti Pharma(ACST-X) 

March 29, 2018

A company with no revenue now. Drug developer. They are into phase 3 trials. A $33 million market cap company with half that in cash in their balance sheet. Probably going to be taken out by a large pharma once the drug is approved. (Analysts’ price target is $5.21)

Consumer Products
0 0 0 0 0
0 comments

A company with no revenue now. Drug developer. They are into phase 3 trials. A $33 million market cap company with half that in cash in their balance sheet. Probably going to be taken out by a large pharma once the drug is approved. (Analysts’ price target is $5.21)

Consumer Products
0 0 0 0 0
0 comments
Alex Ruus

Portfolio , Arrow Capital Manage...

Price Price
$1.300
Owned Owned
Yes

STRONG BUY
Acasti Pharma(ACST-X) 

January 16, 2018

Got beaten up recently, because they just did a financing. (He has 3% of the financing.) A compelling opportunity and a great entry point. They are going to be initiating phase 3 trials this month. Just raised some money and have enough to do the trial now. In negotiations with a big Chinese Pharma in terms of licensing Asian rights. Has been presented with an opportunity for about $125 million deal with the Chinese, which they are still negotiating. They have the cash on the balance sheet, so there are no near-term financial pressures.

Consumer Products
0 0 0 0 0
0 comments

Got beaten up recently, because they just did a financing. (He has 3% of the financing.) A compelling opportunity and a great entry point. They are going to be initiating phase 3 trials this month. Just raised some money and have enough to do the trial now. In negotiations with a big Chinese Pharma in terms of licensing Asian rights. Has been presented with an opportunity for about $125 million deal with the Chinese, which they are still negotiating. They have the cash on the balance sheet, so there are no near-term financial pressures.

Consumer Products
0 0 0 0 0
0 comments
Alex Ruus

Portfolio , Arrow Capital Manage...

Price Price
$1.160
Owned Owned
Yes

BUY
Acasti Pharma(ACST-X) 

September 27, 2017

A spin-out out of Neptune (NEPT-T), which still owns 35% of the company. There are positive developments going on and they are getting very close to going forward with phase 3. Discussions have been going on with the FDA. It’s fallen off the radar screen and there isn’t much in terms of analysts’ coverage. Expects there will be news this fall and winter which should really catalyze the stock. A good time to accumulate the stock.

Consumer Products
0 0 0 0 0
0 comments

A spin-out out of Neptune (NEPT-T), which still owns 35% of the company. There are positive developments going on and they are getting very close to going forward with phase 3. Discussions have been going on with the FDA. It’s fallen off the radar screen and there isn’t much in terms of analysts’ coverage. Expects there will be news this fall and winter which should really catalyze the stock. A good time to accumulate the stock.

Consumer Products
0 0 0 0 0
0 comments
Alex Ruus

Portfolio , Arrow Capital Manage...

Price Price
$1.630
Owned Owned
Unknown

COMMENT
Acasti Pharma(ACST-X) 

January 2, 2015

Acasti Pharma (APO-X) and Neptune Tech & Bioresource (NTB-T) comparison? The key for both companies is the use of krill to extract fish oil. The target would be for high lipids in blood. They can be taken alone or used in combination with statin drugs. The testing has been finished and it works. This stock is covered by only one analyst who is forecasting they are going to lose $0.06 in February year end, but will turn around and earn $0.22 in 2016. Speculative.

Consumer Products
0 0 0 0 0
0 comments

Acasti Pharma (APO-X) and Neptune Tech & Bioresource (NTB-T) comparison? The key for both companies is the use of krill to extract fish oil. The target would be for high lipids in blood. They can be taken alone or used in combination with statin drugs. The testing has been finished and it works. This stock is covered by only one analyst who is forecasting they are going to lose $0.06 in February year end, but will turn around and earn $0.22 in 2016. Speculative.

Consumer Products
0 0 0 0 0
0 comments
Robert McWhirte

President, Selective Asset Mana...

Price Price
$0.600
Owned Owned
Unknown

COMMENT
Acasti Pharma(ACST-X) 

December 10, 2014

Thinks there will be an event next year that will get the stock up above $1. Has been a poor performer this year. At the end of September, they came out with phase II trial results on their big Capri drug. Trial results were good. The current drug is a multimillion dollar drug that reduces triglyceride by 20%. This company’s drug, with half the dosage, came out with a 40% reduction. Because there were a bunch of short term players that when the stock didn’t pop a lot immediately, they decided to bail which has put on some selling pressure. For a company with a $30 million Enterprise Value, you are investing in something that would probably be in the half billion dollar range in the US. There is huge upside in the stock. New management is coming in, and once the phase 3 trial comes in, you are likely to see the stock really accelerate upwards.

Consumer Products
0 0 0 0 0
0 comments

Thinks there will be an event next year that will get the stock up above $1. Has been a poor performer this year. At the end of September, they came out with phase II trial results on their big Capri drug. Trial results were good. The current drug is a multimillion dollar drug that reduces triglyceride by 20%. This company’s drug, with half the dosage, came out with a 40% reduction. Because there were a bunch of short term players that when the stock didn’t pop a lot immediately, they decided to bail which has put on some selling pressure. For a company with a $30 million Enterprise Value, you are investing in something that would probably be in the half billion dollar range in the US. There is huge upside in the stock. New management is coming in, and once the phase 3 trial comes in, you are likely to see the stock really accelerate upwards.

Consumer Products
0 0 0 0 0
0 comments
Alex Ruus

Portfolio , Arrow Capital Manage...

Price Price
$0.470
Owned Owned
Yes

STRONG BUY
Acasti Pharma(ACST-X) 

December 6, 2013

Developing a revolutionary cholesterol/glycerids treatment (CaPre). Had to finance to raise money for a phase 3 trial. A table pounding buy. Stock has been beaten up on short-term concerns. Looking for this to double or triple in the next year.

Consumer Products
0 0 0 0 0
0 comments

Developing a revolutionary cholesterol/glycerids treatment (CaPre). Had to finance to raise money for a phase 3 trial. A table pounding buy. Stock has been beaten up on short-term concerns. Looking for this to double or triple in the next year.

Consumer Products
0 0 0 0 0
0 comments
Alex Ruus

Portfolio , Arrow Capital Manage...

Price Price
$1.250
Owned Owned
Yes

STRONG BUY
Acasti Pharma(ACST-X) 

September 4, 2013

(Market Call Minute.) Doing two phase 2 trials. Good results. (See Top Picks).

Consumer Products
0 0 0 0 0
0 comments

(Market Call Minute.) Doing two phase 2 trials. Good results. (See Top Picks).

Consumer Products
0 0 0 0 0
0 comments
Alex Ruus

Portfolio , Arrow Capital Manage...

Price Price
$2.400
Owned Owned
Yes

Showing 1 to 8 of 8 entries
Successfully Saved Company
Successfully Saved Company